Supplement: Current and Emerging Treatment Approaches Address Unmet Needs in Glaucoma Care

Injectable devices that can monitor IOP and adjust therapy 24/7 are on the horizon

Howard Larkin

Posted: Tuesday, September 21, 2021

Sustained-release implants and micro- or minimally invasive glaucoma surgeries (MIGS) are emerging therapies that address key unmet needs in glaucoma treatment. By broadening the spectrum of
interventions, these therapies allow glaucoma specialists to consider more measured approaches earlier in disease progression, with a view to delay as well as safeguard the possibility of further invasive surgeries.
Drs. Herbert Reitsamer, Andrew Tatham, and Iqbal Ike K. Ahmed discuss how patient compliance impacts glaucoma progression, the role of sustained-release drug delivery and MIGS in alleviating patient treatment burden, the use of MIGS in combination with cataract surgery, and how these therapies can be incorporated into the treatment paradigm.

Download Supplement – click here